Table 2. Distribution of RTKs, MED12, and TGF-βRII stratified by IHC total score in SCLC tumors as shown in Figure 2 (n=125).
| Molecules | TS=0 | TS=2 | TS=3 | TS=4 | TS=5 | TS=6 | NE |
|---|---|---|---|---|---|---|---|
| c-kit | 9 (7.2) | 2 (1.6) | 7 (5.6) | 29 (23.2) | 40 (32.0) | 38 (30.4) | 0 (0) |
| HER2 | 88 (70.4) | 18 (14.4) | 8 (6.4) | 6 (4.8) | 5 (4.0) | 0 (0) | 0 (0) |
| c-Met | 1 (0.8) | 0 (0) | 4 (3.2) | 38 (30.4) | 61 (48.8) | 20 (16.0) | 1 (0.8) |
| VEGFRII | 79 (63.2) | 10 (8.0) | 15 (12.0) | 16 (12.8) | 4(3.2) | 0 (0) | 1 (0.8) |
| EGFR | 84 (67.2) | 12 (9.6) | 10 (8.0) | 13 (10.4) | 4 (3.2) | 1 (0.8) | 1 (0.8) |
| ALK | 125 (100) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| MED12 | 0 (0) | 0 (0) | 1 (0.8) | 9 (7.2) | 56 (44.8) | 59 (47.2) | 0 (0) |
| TGF-βRII | 2 (1.6) | 2 (1.6) | 6 (4.8) | 46 (36.8) | 60 (48.0) | 9 (7.2) | 0 (0) |
RTK, receptor tyrosine kinase; MED12, mediator complex subunit 12; TGF, transforming growth factor; IHC, immunohistochemistry; SCLC, small-cell lung cancer; TS, total score; NE, not evaluable; HER2, human EGFR-related 2; VEGFR, vascular endothelial growth factor receptor; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase. Numbers in parentheses show percentages.